Eli Lilly's SURMOUNT-1 study evaluated tirzepatide for treating pre-diabetic and obese individuals over 176 weeks. Results showed significant weight loss, decreased risk of developing type 2 diabetes, and improved health outcomes.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing